drugset / Trial / NCT05462587
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II
RandomizedCrossoverDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Timeline
- Start
- 2022-07-28
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVTX-803 | Unknown | 1700 mg/kg | — |